Body composition and chemotherapy toxicity among women treated for breast cancer: a systematic review.
Body composition
Breast cancer
Chemotherapy
Toxicity
Journal
Journal of cancer survivorship : research and practice
ISSN: 1932-2267
Titre abrégé: J Cancer Surviv
Pays: United States
ID NLM: 101307557
Informations de publication
Date de publication:
24 Apr 2023
24 Apr 2023
Historique:
received:
31
01
2023
accepted:
08
04
2023
medline:
24
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
aheadofprint
Résumé
Toxicity is a significant problem among women receiving systemic chemotherapy for breast cancer, with up to 60% experiencing hematologic and 14% experiencing non-hematologic toxicity. Chemotherapy is dosed using body surface area, which does not account for heterogeneity in lean body mass (LBM) and adipose tissue (AT). This systematic review, registered with the PROSPERO International Prospective Register of Systematic Reviews (#CRD42021279874), evaluates associations between body composition and chemotherapy-related toxicity during breast cancer treatment. Scientific literature databases (PubMed, Scopus, CINAHL, and CENTRAL) were systematically searched in November 2021 for studies evaluating associations between body composition (assessed using computed tomography or dual x-ray absorptiometry) and chemotherapy-related toxicity among women receiving breast cancer treatment. Eligibility was not limited by year or country of publication. Article screening and data abstraction was conducted using the Covidence Systematic Review Management System. Predetermined criteria were used to evaluate rigor of participant recruitment, representativeness of the population, and use of validated measures of body composition and toxicity. An inverse association between LBM and toxicity was reported in seven of the eight included studies, although definitions of low LBM differed across studies. Three studies evaluated the association between AT and chemotherapy toxicity with inconsistent findings. Heterogeneity in body composition measures/definitions and treatment regimens precluded the ability to perform meta-analyses. Low LBM appears to be a risk factor for chemotherapy toxicity, but the role of AT is unclear. Further research that accounts for guideline concordance in chemotherapy prescriptions and the use of supportive care medications is needed.
Identifiants
pubmed: 37093518
doi: 10.1007/s11764-023-01380-7
pii: 10.1007/s11764-023-01380-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : R21 CA259790
Pays : United States
Organisme : NIH HHS
ID : R21 CA259790
Pays : United States
Organisme : NIH HHS
ID : R21 CA259790
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Aleixo GFP, Shachar SS, Deal AM, Nyrop KA, Muss HB, Chen YT, Yu H, Williams GR. The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer. Breast Cancer Res Treat. 2020;182:631–42.
doi: 10.1007/s10549-020-05731-1
pubmed: 32519169
Brown JC, Cespedes Feliciano EM, Caan BJ. The evolution of body composition in oncology-epidemiology, clinical trials, and the future of patient care: facts and numbers. J Cachexia Sarcopenia Muscle. 2018;9:1200–8.
doi: 10.1002/jcsm.12379
pubmed: 30637983
Caan BJ, Cespedes Feliciano EM, Prado CM, Alexeeff S, Kroenke CH, Bradshaw P, Quesenberry CP, Weltzien EK, Castillo AL, Olobatuyi TA, Chen WY. Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer JAMA. Oncology. 2018;4:798–804.
Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest. 2019;129:3006–17.
doi: 10.1172/JCI127201
pubmed: 31264969
pmcid: 6668696
Cespedes Feliciano EM, Chen WY, Lee V, Albers KB, Prado CM, Alexeeff S, Xiao J, Shachar SS, Caan BJ. Body composition, adherence to anthracycline and taxane-based chemotherapy, and survival after nonmetastatic breast cancer. JAMA Oncol. 2020;6(2):264–70.
doi: 10.1001/jamaoncol.2019.4668
pubmed: 31804676
Fay ME, Myers DR, Kumar A, Turbyfield CT, Byler R, Crawford K, Mannino RG, Laohapant A, Tyburski EA, Sakurai Y, Rosenbluth MJ, Switz NA, Sulchek TA, Graham MD, Lam WA. Cellular softening mediates leukocyte demargination and trafficking, thereby increasing clinical blood counts. Proc Natl Acad Sci U S A. 2016;113:1987–92.
doi: 10.1073/pnas.1508920113
pubmed: 26858400
pmcid: 4776450
Gouerant S, Leheurteur M, Chaker M, Modzelewski R, Rigal O, Veyret C, Lauridant G, Clatot F. A higher body mass index and fat mass are factors predictive of docetaxel dose intensity. Anticancer Res. 2013;33:5655–62.
pubmed: 24324113
Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, Dinner S, Geyer M, Glaspy J, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Mahajan A, Miller R, Nachar V, Patel S, Patel S, Perez LE, Poust A, Riaz F, Rosovsky R, Rugo HS, Simon S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Berardi RA, Pluchino L. NCCN guidelines® Insights: hematopoietic growth factors, version 1.2022. J Natl Compr Cancer Netw. 2022;20:436–42.
doi: 10.6004/jnccn.2022.0026
Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30:1553–61.
doi: 10.1200/JCO.2011.39.9436
pubmed: 22473167
Huiskamp LFJ, Chargi N, Devriese LA, May AM, Huitema ADR, de Bree R. The predictive value of low skeletal muscle mass assessed on cross-sectional imaging for anti-cancer drug toxicity: a systematic feview and meta-analysis. J Clin Med. 2020;9(11):3780.
doi: 10.3390/jcm9113780
pubmed: 33238530
pmcid: 7700117
Mazzuca F, Onesti CE, Roberto M, Di Girolamo M, Botticelli A, Begini P, Strigari L, Marchetti P, Muscaritoli M. Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Oncotarget. 2018;9:25714–22.
doi: 10.18632/oncotarget.25394
pubmed: 29876019
pmcid: 5986630
Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007;25:3699–704.
doi: 10.1200/JCO.2007.10.9710
pubmed: 17704418
Nikolaus CJ, An R, Ellison B, Nickols-Richardson SM. Food insecurity among college students in the United States: a scoping review. Adv Nutr (Bethesda, Md). 2020;11:327–48.
doi: 10.1093/advances/nmz111
Ofenheimer A, Breyer-Kohansal R, Hartl S, Burghuber OC, Krach F, Schrott A, Wouters EFM, Franssen FME, Breyer MK. Reference values of body composition parameters and visceral adipose tissue (VAT) by DXA in adults aged 18–81 years-results from the LEAD cohort. Eur J Clin Nutr. 2020;74:1181–91.
doi: 10.1038/s41430-020-0596-5
pubmed: 32123345
pmcid: 7402993
Pamoukdjian F, Bouillet T, Lévy V, Soussan M, Zelek L, Paillaud E. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review. Clin Nutr. 2018;37:1101–13.
doi: 10.1016/j.clnu.2017.07.010
pubmed: 28734552
Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15:2920–6.
doi: 10.1158/1078-0432.CCR-08-2242
pubmed: 19351764
Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, Mackey JR, Kuzma M, Damaraju VL, Sawyer MB. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol. 2011;67:93–101.
doi: 10.1007/s00280-010-1288-y
pubmed: 20204364
Shachar SS, Deal AM, Weinberg M, Nyrop KA, Williams GR, Nishijima TF, Benbow JM, Muss HB. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res. 2017;23:658–65.
doi: 10.1158/1078-0432.CCR-16-0940
pubmed: 27489287
Shachar SS, Deal AM, Weinberg M, Williams GR, Nyrop KA, Popuri K, Choi SK, Muss HB. Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for early-stage breast cancer. Clin Cancer Res. 2017;23:3537–43.
doi: 10.1158/1078-0432.CCR-16-2266
pubmed: 28143874
pmcid: 5511549
Sheng X, Parmentier JH, Tucci J, Pei H, Cortez-Toledo O, Dieli-Conwright CM, Oberley MJ, Neely M, Orgel E, Louie SG, Mittelman SD. Adipocytes sequester and metabolize the chemotherapeutic daunorubicin. Mol Cancer Res. 2017;15:1704–13.
doi: 10.1158/1541-7786.MCR-17-0338
pubmed: 29117945
pmcid: 5726435
Shoenfeld Y, Gurewich Y, Gallant LA, Pinkhas J. Prednisone-induced leukocytosis influence of dosage, method and duration of administration on the degree of leukocytosis. Am J Med. 1981;71:773–8.
doi: 10.1016/0002-9343(81)90363-6
pubmed: 7304648
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199–212.
doi: 10.1200/JCO.2015.62.3488
pubmed: 26169616
Ueno A, Yamaguchi K, Sudo M, Imai S. Sarcopenia as a risk factor of severe laboratory adverse events in breast cancer patients receiving perioperative epirubicin plus cyclophosphamide therapy. Support Care Cancer. 2020;28(9):4249–54.
doi: 10.1007/s00520-019-05279-x
pubmed: 31900607
van den Berg M, Kok DE, Posthuma L, Kamps L, Kelfkens CS, Buist N, Geenen M, Haringhuizen A, Heijns JB, van Lieshout R, Los M, Sommeijer DW, Timmer-Bonte JNH, de Kruif A, van Laarhoven HWM, Kampman E, Winkels RM. Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I-IIIB breast cancer receiving chemotherapy. Breast Cancer Res Treat. 2019;173:475–81.
doi: 10.1007/s10549-018-5014-5
pubmed: 30353244
Weinberg MS, Shachar SS, Muss HB, Deal AM, Popuri K, Yu H, Nyrop KA, Alston SM, Williams GR. Beyond sarcopenia: Characterization and integration of skeletal muscle quantity and radiodensity in a curable breast cancer population. Breast J. 2018;24:278–84.
doi: 10.1111/tbj.12952
pubmed: 29139618
Wong AL, Seng KY, Ong EM, Wang LZ, Oscar H, Cordero MT, Copones R, Fan L, Tan SH, Goh BC, Lee SC. Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat. 2014;144:143–52.
doi: 10.1007/s10549-014-2843-8
pubmed: 24481679